Skip to content
- Replimune Gets Third Try at FDA Approval After Makary Departure WSJ
- Replimune to resubmit twice-rejected drug for approval after FDA shakeup CNBC
- Replimune Soars After FDA Reconsiders Denial of Skin Cancer Drug Bloomberg.com
- Replimune plans RP1 resubmission to FDA (REPL:NASDAQ) Seeking Alpha
- Replimune Group, Inc. Announces FDA Alignment on Path Forward for BLA Resubmission of RP1 for Advanced Melanoma Treatment Quiver Quantitative